Story perspectives

FDA Approves Two New Antibiotics to Combat Gonorrhea Surge

12/13/2025

Summary

Story summary

The U.S. Food and Drug Administration has approved two new antibiotics, zoliflodacin (Nuzolvence) and gepotidacin (Blujepa), to treat gonorrhea, as the infection becomes more resistant to existing treatments.
Zoliflodacin is a single-dose oral treatment, while gepotidacin is administered in two doses.
Experts caution that ongoing development of new treatments is necessary due to concerns about potential resistance.
Gonorrhea cases have surged, with sexually transmitted infections increasing by 90% since 2004.

1 of 1

Story summary

The U.S. Food and Drug Administration has approved two new antibiotics, zoliflodacin (Nuzolvence) and gepotidacin (Blujepa), to treat gonorrhea, as the infection becomes more resistant to existing treatments.
Zoliflodacin is a single-dose oral treatment, while gepotidacin is administered in two doses.
Experts caution that ongoing development of new treatments is necessary due to concerns about potential resistance.
Gonorrhea cases have surged, with sexually transmitted infections increasing by 90% since 2004.